Company intelligence / Profile preview

Cancer Therapeutics CRC

Melbourne, Victoria, Australiacancerresearchhorizons.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cancer Therapeutics CRC was a major Australian collaborative initiative focused on translating academic cancer biology into new small molecule drugs. It commercialized multiple drug discovery projects, secured over $40 million in licensing revenue, and executed significant preclinical licensing deals with international pharmaceutical companies. The organization provided seed funding for the Zero Childhood Cancer program and influenced regulatory policy for early metastasis drugs. Operations were wound up in December 2020, with some activities transitioning to Canthera Discovery[5].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Academic Hospital/University/Research

Partnerships

PfizerNumerous Australian research institutesNumerous Australian universitiesNumerous Australian biotechnology companies

Beyond the preview

Go deeper on Cancer Therapeutics CRC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancer Therapeutics CRC.

Explore the full profile